Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells

Cancer Biology and Therapy

Volumn 6, Issue 3, 2007, Pages 367-376

  Kusumawidjaja, Grace ^a   Kayed, Hany ^a   Giese, Nathalia ^a   Bauer, Andrea ^b   Erkan, Mert ^a   Giese, Thomas ^a   Hoheisel, Jörg D ^b   Friess, Helmut ^a   Kleeff, Jörg ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; BTF3; Chemotherapy; EPHB2; Microarray; Pancreatic cancer; Radiotherapy

Indexed keywords

BASIC TRANSCRIPTION FACTOR 3; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; TRANSCRIPTION REGULATION;

EID: 34548240629     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.3.3704     Document Type: Article

References (64)

1. Zheng XM, Moncollin V, Egly JM, Chambon P. A general transcription factor forms a stable complex with RNA polymerase B (II). Cell 1987; 50:361-8.
2. Cavallini B, Faus I, Matthes H, Chipoulet JM, Winsor B, Egly JM, Chambon P. Cloning of the gene encoding the yeast protein BTF1Y, which can substitute for the human TATA box-binding factor. Proc Natl Acad Sci USA 1989; 86:9803-7.
3. Cavallini B, Huet J, Plassat JL, Sentenac A, Egly JM, Chambon P. A yeast activity can substitute for the HeLa cell TATA box factor. Nature 1988; 334:77-80.
4. Kanno M, Chalut C, Egly JM. Genomic structure of the putative BTF3 transcription factor. Gene 1992; 117:219-28.
5. Zheng XM, Black D, Chambon P, Egly JM. Sequencing and expression of complementary DNA for the general transcription factor BTF3. Nature 1990; 344:556-9.
6. Wynick D, Small CJ, Bacon A, Holmes FE, Norman M, Ormandy CJ, Kilic E, Kerr NC, Ghatei M, Talamantes F, Bloom SR, Pachnis V. Galanin regulates prolactin release and lactotroph proliferation. Proc Natl Acad Sci USA 1998; 95:12671-6.
7. Deng JM, Behringer RR. An insertional mutation in the BTF3 transcription factor gene leads to an early postimplantation lethality in mice. Transgenic Res 1995; 4:264-9.
8. Bloss TA, Witze ES, Rothman JH. Suppression of CED-3-independent apoptosis by mito- mitochondrial βNAC in Caenorhabditis elegans. Nature 2003; 424:1066-71.
9. Brockstedt E, Otto A, Rickers A, Bommert K, Wittmann-Liebold B. Preparative high-resolution two-dimensional electrophoresis enables the identification of RNA polymerase B transcription factor 3 as an apoptosis-associated protein in the human BL60-2 Burkitt lymphoma cell line. J Protein Chem 1999; 18:225-31.
10. Thiede B, Dimmler C, Siejak F, Rudel T. Predominant identification of RNA-binding proteins in Fas-induced apoptosis by proteome analysis. J Biol Chem 2001; 276:26044-50.
11. Li R, Liu XL, Du QF, Zhang S, Luo RC, Zhou SY. Proteome analysis of apoptotic K562 cells induced by harringtonine. Zhonghua Xue Ye Xue Za Zhi 2004; 25:323-7.
12. Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, Zanotti B, Skrap M, Pizzolitto S, Stanta G, Vindigni A. Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 2005; 4:698-708.
13. Dunican DS, McWilliam P, Tighe O, Parle-McDermott A, Croke DT. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene 2002; 21:3253-7.
14. Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-Olson JF, Korc M, Hammer J, Buchler MW. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003; 60:1180-99.
15. Friess H, Ding J, Kleeff J, Liao Q, Berberat PO, Hammer J, Buchler MW. Identification of disease-specific genes in chronic pancreatitis using DNA array technology. Ann Surg 2001; 234:769-78, (discussion 78-9).
16. Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buchler MW, Friess H. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 2004; 23:71-81.
17. Kayed H, Kleeff J, Keleg S, Guo J, Ketterer K, Berberat PO, Giese N, Esposito I, Giese T, Buchler MW, Friess H. Indian hedgehog signaling pathway: Expression and regulation in pancreatic cancer. Int J Cancer 2004; 110:668-76.
18. Guo DL, Zhang J, Yuen ST, Tsui WY, Chan AS, Ho C, Ji J, Leung SY, Chen X. Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 2006; 27:454-64.
19. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999; 18:5363-72.
20. Esposito I, Bauer A, Hoheisel JD, Kleeff J, Friess H, Bergmann F, Rieker RJ, Otto HF, Kloppel G, Penzel R. Microcystic tubulopapillary carcinoma of the pancreas: A new tumor entity? Virchows Arch 2004; 444:447-53.
21. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α. J Clin Invest 1992; 90:1352-60.
22. Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, Vingron M. Correspondence analysis applied to microarray data. Proc Natl Acad Sci USA 2001; 98:10781-6.
23. Fellenberg K, Hauser NC, Brors B, Hoheisel JD, Vingron M. Microarray data warehouse allowing for inclusion of experiment annotations in statistical analysis. Bioinformatics 2002; 18:423-33.
24. Beissbarth T, Fellenberg K, Brors B, Arribas-Prat R, Boer J, Hauser NC, Scheideler M, Hoheisel JD, Schutz G, Poustka A, Vingron M. Processing and quality control of DNA array hybridization data. Bioinformatics 2000; 16:1014-22.
25. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001; 29:365-71.
26. Kleeff J, Ishiwata T, Friess H, Buchler MW, Israel MA, Korc M. The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res 1998; 58:3769-72.
27. Maruyama H, Kleeff J, Wildi S, Friess H, Buchler MW, Israel MA, Korc M. Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol 1999; 155:815-22.
28. Kleeff J, Friess H, Simon P, Susmallian S, Buchler P, Zimmermann A, Buchler MW, Korc M. Overexpression of Smad2 and co-localization with TGF-β1 in human pancreatic cancer. Dig Dis Sci 1999; 44:1793-802.
29. Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D, Korc M. Smad6 suppresses TGF-β-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 1999; 255:268-73.
30. Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, Kuwai T, Abbruzzese JL, Fidler IJ. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 2005; 65:10371-80.
31. Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. Expert Opin Pharmacother 2006; 7:177-93.
32. Jeong J, Choi S, Gu C, Lee H, Park S. Genomic structure and promoter analysis of the mouse EphA8 receptor tyrosine kinase gene. DNA Cell Biol 2000; 19:291-300.
33. Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, Ellis LM. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002; 94:934-9.
34. Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tornillo L. EphB2 expression across 138 human tumor types in a tissue microarray: High levels of expression in gastrointestinal cancers. Clin Cancer Res 2005; 11:6450-8.
35. Kataoka H, Tanaka M, Kanamori M, Yoshii S, Ihara M, Wang YJ, Song JP, Li ZY, Arai H, Otsuki Y, Kobayashi T, Konno H, Hanai H, Sugimura H. Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. J Cancer Res Clin Oncol 2002; 128:343-8.
36. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004; 50:490-9.
37. Davalos V, Dopeso H, Velho S, Ferreira AM, Cirnes L, Diaz-Chico N, Bilbao C, Ramirez R, Rodriguez G, Falcon O, Leon L, Niessen RC, Keller G, Dallenbach-Hellweg G, Espin E, Armengol M, Plaja A, Perucho M, Imai K, Yamamoto H, Gebert JF, Diaz-Chico JC, Hofstra RM, Woerner SM, Seruca R, Schwartz S, Arango D. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene 2006.
38. Salvucci O, Sierra MD, Martina JA, McCormick PJ, Tosato G. EphB2 and EphB4 receptors forward signaling promotes SDF- 1-induced endothelial cell chemotaxis and branching remodeling. Blood 2006.
39. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89:1260-70.
40. Fidler IJ, Radinsky R. Search for genes that suppress cancer metastasis. J Natl Cancer Inst 1996; 88:1700-3.
41. Fidler IJ. Critical determinants of cancer metastasis: Rationale for therapy. Cancer Chemother Pharmacol 1999; 43(Suppl):S3-10.
42. Nakajima M, Irimura T, Nicolson GL. A solid-phase substrate of heparanase: Its application to assay of human melanoma for heparan sulfate degradative activity. Anal Biochem 1986; 157:162-71.
43. Nakajima M, Irimura T, Nicolson GL. Tumor metastasis-associated heparanase (heparan sulfate endoglycosidase) activity in human melanoma cells. Cancer Lett 1986; 31:277-83.
44. Xiao Y, Kleeff J, Shi X, Buchler MW, Friess H. Heparanase expression in hepatocellular carcinoma and the cirrhotic liver. Hepatol Res 2003; 26:192-8.
45. Jiang P, Kumar A, Parrillo JE, Dempsey LA, Platt JL, Prinz RA, Xu X. Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: Role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem 2002; 277:8989-98.
46. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001; 61:4655-9.
47. Cong XL, Li B, Yang RC, Feng SZ, Chen SJ, Han ZC. Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy. Leukemia 2005; 19:1517-24.
48. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A, Lemoine NR. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002; 21:4587-94.
49. Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat Res 2005; 569:123-32.
50. Vorechovsky I, Rasio D, Luo L, Monaco C, Hammarstrom L, Webster AD, Zaloudik J, Barbanti-Brodani G, James M, Russo G, et al. The ATM gene and susceptibility to breast cancer: Analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res 1996; 56:2726-32.
51. Vorechovsky I, Luo L, Lindblom A, Negrini M, Webster AD, Croce CM, Hammarstrom L. ATM mutations in cancer families. Cancer Res 1996; 56:4130-3.
52. Morgan SE, Kastan MB. p53 and ATM: Cell cycle, cell death, and cancer. Adv Cancer Res 1997; 71:1-25.
53. Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: The gatekeepers and the caretakers. Am J Clin Pathol 2005; 124(Suppl):S16-2).
54. Yu G, Zhu MH, Zhu Z, Ni CR, Zheng JM, Li FM. Expression of ATM protein and its relationship with p53 in pancreatic carcinoma with tissue array. Pancreas 2004; 28:421-6.
55. Heighway J, Betticher DC, Hoban PR, Altermatt HJ, Cowen R. Coamplification in tumors of KRAS2, type 2 inositol 1,4,5 triphosphate receptor gene, and a novel human gene, KRAG. Genomics 1996; 35:207-14.
56. Arora S, Matta A, Shukla NK, Deo SV, Ralhan R. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 2005; 42:97-108.
57. Sharma R, Sud N, Chattopadhyay TK, Ralhan R. TC21/R-Ras2 upregulation in esophageal tumorigenesis: Potential diagnostic implications. Oncology 2005; 69:10-8.
58. Clark GJ, Kinch MS, Gilmer TM, Burridge K, Der CJ. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 1996; 12:169-76.
59. Barker KT, Crompton MR. Ras-related TC21 is activated by mutation in a breast cancer cell line, but infrequently in breast carcinomas in vivo. Br J Cancer 1998; 78:296-300.
60. Schlossmann J, Ammendola A, Ashman K, Zong X, Huber A, Neubauer G, Wang GX, Allescher HD, Korth M, Wilm M, Hofmann F, Ruth P. Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ib. Nature 2000; 404:197-201.
61. Imamura M. Pancreatic endocrine tumor-from clinic to calcium sensing receptor. Hum Cell 2000; 13:65-9.
62. Yamamoto M, Nakano S, Mugikura M, Tachibana I, Ogami Y, Otsuki M. Pancreatic cancer and hypercalcemia associated with von Recklinghausen's disease. J Gastroenterol 1996; 31:728-31.
63. Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002; 16:1053-68.
64. Shishodia S, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBα kinase in human nonsmall cell lung carcinoma: Correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 2004; 64:5004-12.